Trillion-yuan state-owned enterprise Guangming Group partners with Guobang Pharmaceutical to invest in bio-manufacturing!
On 6/15, the state-owned enterprise Guangming Food Group, with assets of over 100 billion yuan, and Guobang Pharmaceutical, a leading listed company in active pharmaceutical ingredients (APIs), officially signed a fund investment agreement to establish a strategic partnership.
6 15,Guangming Food Group, a state-owned enterprise with assets exceeding 100 billion yuan, and Guobang Pharmaceutical, a leading listed company in the API sectorFormally signed the fund investment agreement and established a strategic partnership.
Both parties intend to jointly contribute capital5 hundred million yuanEstablish the "Guangming Guobang Investment Fund." Guobang Medicine's wholly-owned subsidiary, Guobang Investment, will contribute 2.5 billion yuan, accounting for 50% of the fund's committed capital. The Shanghai Yimin Food No. 1 Factory (Group) Co., Ltd., part of the Guangming Group, will contribute nearly 2.5 billion yuan.
Against the backdrop of a trillion-dollar biomanufacturing boom, a powerful cross-industry partnership spanning food, health, and pharmaceutical manufacturing has officially launched.
Registration is now open: Secure your spot at the premier industry event.
2026 (2nd) Yitao Bio-Manufacturing Industry Conference & Exhibition (Summer) – Full Category Registration Now Open. Limited-Time Early Bird Benefits Also ActiveScan the QR code to view ticket types and corresponding benefits, then choose the best conference plan for you. Register now and get approved instantly—early registration secures limited spots and unlocks core perks like exhibition access and forum participation.
[$5B Fund: What to Invest In? How to Invest?]
According to the cooperation agreement, Guangming Guobang Investment Fund will focus its investments on three key areas:
First, high-end pharmaceutical manufacturing and the innovative drug industry chain.This is Guobang Pharmaceutical's core expertise and the most predictable growth track, covering specialty APIs, innovative drug intermediates, CDMO services, and veterinary biologics to advance domestic substitution of high-end pharmaceutical raw materials.
Second, intelligent green biomanufacturing and pharmaceutical production.This is the core intersection of both parties' strategic synergy—Guangming brings industrial scenarios and capital strength, while Guobang offers technical expertise and manufacturing capabilities. We will focus on incubating cutting-edge technologies such as synthetic biology, enzyme catalysis, and strain engineering, and deploy low-carbon bio-fermentation, smart factories, and bio-based new materials projects to address the pain points of high pollution and high energy consumption in traditional chemical manufacturing.
Third, the broader health sector, including food and consumer goods.Leverage Bright Food's industrial foundation to advance the commercialization of biomanufacturing technologies in functional foods, nutritional additives, and healthy ingredients.
[Step on the Beat of the Times: The Bio-Manufacturing Boom Has Arrived]
This partnership stands out not just for the scale of both parties, but because it perfectly aligns with current market trends.
Biomanufacturing has been officially integrated into the nation's future industry strategy.The "15th Five-Year Plan" outline explicitly identifies quantum technologies, bio-manufacturing, hydrogen and nuclear fusion energy, brain-computer interfaces, embodied AI, and sixth-generation mobile communications as new growth engines. From the "14th Five-Year Plan for Bioeconomy Development" to the 2025 Government Work Report—where bio-manufacturing was first categorized under "future industries"—policy signals have become increasingly clear.
Many countries have integrated biomanufacturing into their national strategies: the United States released the "National Biotechnology and Biomanufacturing Plan"; South Korea's National Assembly passed the "Synthetic Biology Promotion Act," establishing synthetic biology as a core national technology; and the UK government issued the "National Vision for Engineering Biology," setting a ten-year strategic plan for the synthetic biomanufacturing industry.Biomanufacturing is considered one of the core drivers of the Fourth Industrial Revolution.By replacing resources with renewable alternatives and deploying carbon reduction technologies, we are reshaping the global industrial system.
Against this backdrop, the entry of state-owned giant Bright Group—a company with assets worth hundreds of billions—represents not only a business decision but also a strategic industrial response to national priorities.
[1 + 1 > 2: A Two-Way Industrial Collaboration]
From a capital perspective, this is a merger of powerhouses.
Guangming Group has long been deeply engaged in the food and health industries.with extensive experience in industrial resources, capital operations, and global expansion. In fact, Bright Group has already quietly established its presence in the field of bio-manufacturing. Earlier this year,The Group's Sugar & Liquor Group and Nanjing Tech University launch industry-university-research collaboration.and signed the "Strategic Cooperation Agreement for Jointly Building the Sugar Industry Bio-manufacturing Technology Innovation and R&D Center" with the National Research Center for Biochemical Engineering Technology. From efficient ensiling of sugarcane tops to research on plant active water, Bright's bio-manufacturing landscape is gradually unfolding.
Guobang Pharmaceutical continues to focus on the life and health sector.Possesses strong manufacturing and industrialization capabilities in the pharmaceutical, animal health, and related supply chain sectors. The company is one of the global leaders in the production of macrolide and quinolone active pharmaceutical ingredients (APIs) and is among China's largest producers of intermediates such as sodium borohydride, potassium borohydride, and cyclopropylamine.
The two parties have strong complementarity in industrial resources, market channels, and technical capabilities.
Strategically, this is a forward-looking initiative.
For Guobang Pharma, this investment will leverage the expertise and resources of professional institutional investors.Gain better insight into investment opportunities in the pharmaceutical innovation value chain, green biomanufacturing, and the broader health sector.
For Guangming Group, this is a pivotal step in extending from "food" to "big health," and a strategic lever for transitioning from "traditional manufacturing" to "bio-intelligent manufacturing."
In the future, both parties will leverage the investment fund platform to advanceStrategic and forward-looking investment in emerging industries and future industriesto achieve industrial collaborative upgrading and shared value creation.
2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)
2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)will be8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Conferences - Meetings - EventsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."
Exhibition FocusMedical Aesthetics, Bio-based Materials & Green Chemicals, Food, Agriculture, and AI EmpowermentExhibitor recruitment is now open. Contact us for details on participating in the exhibition.
